BioSpace News Archive

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full year ended December 31, 2021.

Leading biotechnology company Pluristem Therapeutics Inc. and Israel’s largest food producer Tnuva Group announced the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that Sam Eldessouky, executive vice president and chief financial officer; William Woodfield, senior vice president and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the J.P. Morgan Global High Yield & Leveraged Finance Conference.

Compugen Ltd. announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors.

Rocket Pharmaceuticals, Inc. today reports financial and operational results for the fourth quarter and year ended December 31, 2021.

Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021.

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes.